IMMUNOLOGY2026™ Conference Recordings For Attendees-Targeting IL-22 activity to the gut epithelium confers disease benefit without provoking skin inflammation

Targeting IL-22 activity to the gut epithelium confers disease benefit without provoking skin inflammation

Video Transcription

Video Summary

Ampersand described a platform for tissue-targeted therapeutics using “addresses” (cell-surface markers) and AI/ML-guided antibody discovery to direct drugs only where needed. They applied this to IL-22, a cytokine that supports gut barrier repair but can cause skin toxicity when delivered systemically. Using a gut-selective address, they built AMP220, an engineered IL-22 fused to a targeting antibody. In human cell studies, AMP220 was highly potent in colon cells but inactive in skin cells. In mice, it drove gut target genes while sparing off-target tissues and improved DSS-induced colitis. In cynomolgus monkeys, it produced strong colon responses with minimal systemic inflammation and no skin activation, unlike non-targeted IL-22-Fc. The team concluded AMP220 may enable higher, safer dosing for inflammatory bowel disease and is advancing through IND-enabling studies.

Meta Tag

Date April 18, 2026 1:33 PM - 1:45 PM

Room 153AB

Session Pathophysiology of Cytokines and Chemokines

Speaker Michelle Yen

Track Cytokines and Chemokines and their Receptors (CCR)

Year 2026

Keywords

tissue-targeted therapeutics

AMP220

IL-22

inflammatory bowel disease

gut-selective antibody

April 18, 2026 1:33 PM - 1:45 PM

153AB

Pathophysiology of Cytokines and Chemokines

Michelle Yen

Cytokines and Chemokines and their Receptors (CCR)

2026